GRTX Galera Therapeutics
- 0.179
- +0.004+2.23%
Galera Therapeutics News
Galera Therapeutics (GRTX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.08 dollars, previous value of -0.50 dollars.
Galera Therapeutics (GRTX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.08 dollars, previous value of -0.50 dollars.
Galera Therapeutics | 10-Q: Quarterly report
Galera Therapeutics Q1 2024 GAAP EPS $(0.08) Beats $(0.35) Estimate
Galera Therapeutics Q1 2024 GAAP EPS $(0.08) Beats $(0.35) Estimate
Galera Therapeutics Had Cash and Cash Equivalents of $13.5M at March 31 >GRTX
Galera Therapeutics Had Cash and Cash Equivalents of $13.5M at March 31 >GRTX
Galera Therapeutics: Evaluation of Potential Strategic Alternatives Progresses With Goal to Maximize Stockholder Value >GRTX
Galera Therapeutics: Evaluation of Potential Strategic Alternatives Progresses With Goal to Maximize Stockholder Value >GRTX
Galera Therapeutics 1Q Loss $4.38M >GRTX
Galera Therapeutics 1Q Loss $4.38M >GRTX
Galera Therapeutics Enacts Plan to Deter Hostile Takeovers
Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to
(SEC Amendment) Galera Therapeutics(GRTX.US) 10% Shareholder Buys US$590.42K in Common Stock
$Galera Therapeutics(GRTX.US)$ 10% Shareholder Schneid Yair purchased 2.78 million shares of common stock on Apr 17, 2014 and Apr 17, 18, 19, 2024 at an average price of $0.2124 for a total value of $
Galera Therapeutics Received A Notice Of Allowance For Its U.S Patent Application 17/378,852 Titled "Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability (To Reduce Oral Mucositis In Head-And-Neck Cancer Patients From Chemoradiation)"
Galera Therapeutics Received A Notice Of Allowance For Its U.S Patent Application 17/378,852 Titled "Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability (To Reduce Oral Mucositis In He
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersINVO Bioscience (NASDAQ:INVO) shares increased by 93.4% to $1.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.8 million. As per the press release
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersGalera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, t
Galera Therapeutics, (GRTX) Sees Unprecedented After-Hours Surge
Galera Therapeutics, Inc. (NASDAQ: GRTX) underwent a turbulent trading session on Thursday, experiencing a substantial 8.79% decline. However, as the closing bell rang, investors were greeted with a remarkable afterhours turnaround, witnessing the stock price surge by an extraordinary 32.14%. This unexpected market upheaval has sparked fervent speculation among industry pundits and enthusiasts regarding its ...
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million. Sunshine Biopharma (NASDAQ:SB
Galera Therapeutics GAAP EPS of -$0.10
As Of December 31, 2023, Galera Had Cash And Cash Equivalents Of $18.3M Which Is Expected To Provide Cash Runway Into Q2 Of 2025
As Of December 31, 2023, Galera Had Cash And Cash Equivalents Of $18.3M Which Is Expected To Provide Cash Runway Into Q2 Of 2025
Galera Therapeutics Q4 EPS $(0.10) Beats $(0.35) Estimate
Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.35) by 71.43 percent. This is a 82.76 percent increase over losses of
Galera Therapeutics 4Q Loss/Shr 10c >GRTX
Galera Therapeutics 4Q Loss/Shr 10c >GRTX
On March 26, Galera Therapeutics Received Letter From Nasdaq Staff Indicating That Company Has Not Regained Compliance With Minimum Market Value Of Listed Securities-8K
On March 26, Galera Therapeutics Received Letter From Nasdaq Staff Indicating That Company Has Not Regained Compliance With Minimum Market Value Of Listed Securities-8K
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders inte
Analysis
Price Target
No Data
